Hereditary Angioedema.

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.

[1]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[2]  A. Davis Mechanism of angioedema in first complement component inhibitor deficiency. , 2006, Immunology and allergy clinics of North America.

[3]  N. Monnier,et al.  Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma. , 2006, Molecular immunology.

[4]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[5]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[6]  L. Romics,et al.  Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[7]  M. López-Trascasa,et al.  Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[9]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[10]  J. Church Oxandrolone treatment of childhood hereditary angioedema. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  M. Cicardi,et al.  How do we treat patients with hereditary angioedema. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[12]  A. Davis,et al.  Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. , 2002, The Journal of clinical investigation.

[13]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.

[14]  S. Choquet,et al.  Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.

[15]  K. Binkley,et al.  Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.

[16]  K. Bork,et al.  Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.

[17]  K. Bork,et al.  Hepatocellular adenomas in patients taking danazol for here ditary angiooedema , 1999, The Lancet.

[18]  F. Rosen,et al.  A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema , 1998, Transfusion.

[19]  F. Rosen,et al.  Molecular defects in hereditary angioneurotic edema. , 1997, Proceedings of the Association of American Physicians.

[20]  H. Bürgi,et al.  Type I hereditary angio‐oedema. Variability of clinical presentation and course within two large kindreds , 1997, Journal of internal medicine.

[21]  E. Verpy,et al.  Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. , 1996, American journal of human genetics.

[22]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[23]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[24]  G. Tsokos,et al.  Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. , 1986, The Journal of allergy and clinical immunology.

[25]  M. Frank Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema. , 1979, Arthritis and rheumatism.

[26]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.

[27]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[28]  J. Atkinson,et al.  Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. , 1975, The Journal of allergy and clinical immunology.

[29]  D. Alling,et al.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. , 1972, The New England journal of medicine.

[30]  F. Rosen,et al.  Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. , 1971, The Journal of clinical investigation.

[31]  F. Rosen,et al.  Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.